

INTERIM FORMULARY UPDATE

The following recommendations, made at the July 9, 2010 meeting of the Executive Formulary Committee, are approved:

Product(s) **approved to be added** to the DADS/DSHS Drug Formulary based on New Drug Applications:

Generic Name	Brand Name	Dosage Form	Classification
Benzonatate	Tessalon® Perles	Capsule 100mg, 200mg	Antitussive
Bupropion XL	Wellbutrin XL®	Tablet 150mg, 300mg	Antidepressant
Cetirizine	Zyrtec®	Tablet 5mg, 10mg Chewable Tablet 10mg	Antihistamine
Esomeprazole Reserved Drug	Nexium®	Capsule 20mg, 40mg Suspension packets 10mg, 20mg, 40mg	Proton Pump Inhibitor
Guaifenesin/codeine	Robitussin AC®	Syrup 10mg codeine/100mg guaifenesin per 5ml Tablet: 10mg codeine/300mg guaifenesin	Antitussive
Megestrol	Megace®	Suspension: 400mg/10mg; 625mg/5ml	Appetite Stimulant
Olanzapine pamoate Reserved Drug	Zyprexa® Relprevv™	Injection, long acting: 210mg, 300mg, 405mg	Psychotropics

Product(s) **denied addition** to the DADS/DSHS Drug Formulary based on New Drug Applications:

Generic Name	Brand Name	Dosage Form	Classification
Levalbuterol	Xopenex®	Inhaler; Inhalation solution: 0.31mg/3ml; 0.63mg/3mg; 1.25mg/3ml, 1.25mg/0.5ml	Respiratory Agent: bronchodilators

Product(s) **deleted** from the DADS/DSHS Drug Formulary:

Generic Name	Brand Name	Dosage forms to be deleted	Dosage forms still available
Rosiglitazone	Avandia®	Tablet: 2mg, 4mg, 8mg	None

Product(s) **approved to be added** to the DADS/DSHS Drug Formulary based on Drug Formulary Sectional Review for **Dermatologicals**

Generic Name	Brand Name	Dosage Form	Classification
Betamethasone dipropionate lotion	Maxivate®	Lotion: 5%	Corticosteroids
Benzocaine paste	Orabase-B®	Paste: 20%	Local Anesthetic
Lidocaine	Lidoderm®	Patch: 5%	Local Anesthetic
Vaseline Lip Therapy			Ointment & Lotion bases
Urea	Carmol®	Cream: 10%, 20%, 40% Lotion: 10% 40% Shampoo: 10%	Keratolytic

Recommendations based on Dermatological Review:

- Add Acticin® as a brand name for permethrin 5% cream
- Add Pronto® instead of A-200® as a common trade name for pyrethins/piperonyl butoxide
- Include the strength for the listing of RID®/Pronto® - pyrethins 0.33%/piperonyl butoxide 4%
- Make augmented betamethasone dipropionate as a reserve drug using the same criteria as for clobetasol since both are ultra-high potency
- Add Cormax® and Clobex® as common branded names for clobetasol
- Change clobetasol scalp application 0.05% to solution, topical scalp application
- Add Lokara® as a common branded name for desonide
- Add Derma-Smooth/FS® as a common brand name for fluocinolone for body and scalp oil and Capex® as a branded name for the shampoo
- List the corticosteroids by potency
- Delete benzocaine lotion from the Formulary as it is no longer available
- Delete clobetasol shampoo from the Formulary due to cost as compared to the topical scalp solution

Other **recommendation(s)/addition(s)/revisions(s)** to the DADS/DSHS Drug Formulary

Add the following new dosage strengths:

- pantoprazole (Protonix®) 40 mg suspension packets,
- enoxaparin (Lovenox®) 150mg injection
- ferrous sulfate 160mg
- fenofibrate, nanocrystallized products

Approved:



Ann Richards, Pharm.D. BCPP
Pharmacy Services Director, San Antonio State Hospital